Marci Drees

Marci Drees

Auto-generated profile, based on publicly available information

Marci Drees

Department of Medicine, ChristianaCare , Wilmington, Delaware , USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
NBNiccolo Buetti
Niccolo Buetti
JMJonas Marschall
Jonas Marschall
MDMarci Drees
Marci Drees
MFMohamad G. Fakih
Mohamad G. Fakih
LHLynn Hadaway
Lynn Hadaway
LMLeonard A. Mermel
Leonard A. Mermel

1 January 2013 in Vaccine
Verified
Journal Article
Closed access
MDM. Drees
M. Drees
BTB. Tambourelli
B. Tambourelli
ADA. Denstman
A. Denstman
WZW. Zhang
W. Zhang
RZR. Zent
R. Zent
DED.B. Ehrenthal
D.B. Ehrenthal

21 October 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MDMarci Drees
Marci Drees
DWDavid J Weber
David J Weber
The United States varicella vaccination program has successfully reduced varicella incidence and hospitalizations by ≥90%, consequently reducing the risk of nosocomial exposures. However, patients and healthcare personnel (HCP) continue to introduce varicella zoster virus (VZV) into healthcare settings. Herpes zoster (HZ) is less contagious than varicella, but it can also result in exposures. Unrecognized varicella and HZ may lead to extensive contact investigations, control efforts, and HCP furloughs that result in significant disruption of healthcare activities as well as substantial costs. Robust occupational health and infection prevention programs that ensure healthcare personnel immunity and prompt recognition and isolation of patients with varicella or HZ will lower the risk of VZV transmission and reduce or eliminate the need to furlough exposed HCP and associated costs.

1 October 2001 in Oncology Research and Treatment
Verified
Journal Article
Closed access
PDF file
GHG. Hartung
G. Hartung
RHRalf D. Hofheinz
Ralf D. Hofheinz
AWA. Wein
A. Wein
CRChristian U. Riedel
Christian U. Riedel
ARA. Rost
A. Rost
WQW. Queisser
W. Queisser
Background: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium – folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium – folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump. Patients and Methods: From 1997 to 1998, 51 patients [median age 60 (range 24–77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m2) and S-FA (500 mg/m2) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3–54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8–11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2–22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.